Armodafinil dosage

Protocol

1. 1

   Measure the dose

   Typical Armodafinil dose is 150 mg (Approved doses 150 or 250 mg morning for narcolepsy and OSA; 150 mg one hour pre-shift for shift work). Use a weight-based calculator for individual adjustments.

   Open tool →
2. 2

   Set the frequency

   Administer daily, morning. Half-life of 15 hours anchors the dosing interval.

   Open tool →
3. 3

   Cycle if needed

   No cycling required for approved indications; long-term continuous use documented over 12 months in narcolepsy

   Open tool →
4. 4

   Monitor for side effects

   Watch for: headache; nausea; dizziness; anxiety. Stop or reduce dose if tolerability breaks down.

Why this dose

Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake systems; R-enantiomer of modafinil with longer half-life.

The typical dose (150 mg) reflects Approved doses 150 or 250 mg morning for narcolepsy and OSA; 150 mg one hour pre-shift for shift work. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Armodafinil is administered via the oral route. Oral dosing is straightforward: take with water, with or without food unless specifically noted.

Onset of action runs around 1 hour after administration. Peak effect lands near 3 hours post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Terminal half-life around 15 hours; longer than modafinil racemate

Cycling and tolerance

No cycling required for approved indications; long-term continuous use documented over 12 months in narcolepsy

Effects to expect at typical dose

• FDA approved in 2007 for narcolepsy, shift-work sleep disorder, and OSA residual sleepiness
• R-enantiomer of modafinil; 150 mg armodafinil is roughly equivalent to 200 mg modafinil
• Schedule IV controlled in the US; prescription-only globally
• Longer terminal half-life of about 15 hours produces extended late-day wakefulness coverage
• Same CYP3A4 induction as modafinil; reduces hormonal contraceptive efficacy
• Side-effect profile and dermatologic risk warnings mirror modafinil

Side effects and interactions

Common side effects

• headache
• nausea
• dizziness
• anxiety
• insomnia (with later-day dosing)

Notable interactions

• hormonal contraceptives (major): CYP3A4 induction reduces contraceptive efficacy; use barrier method
• cyclosporine (major): reduced cyclosporine levels via CYP3A4 induction
• MAOIs (major): potential hypertensive reaction
• warfarin (moderate): CYP2C9 inhibition raises INR
• phenytoin (moderate): CYP2C19 inhibition raises phenytoin levels

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Armodafinil profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

banned

DEA / Rx

Schedule IV

Pregnancy

Not recommended

Legal status

Schedule IV (US); prescription-only globally; not a supplement

Do not use if

• recent myocardial infarction
• unstable angina
• left ventricular hypertrophy
• significant arrhythmia
• history of Stevens-Johnson syndrome
• psychotic disorders
• pregnancy
• concurrent MAOI use

Related research